back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2023-12-21 15:52 Tx date 2023-12-21 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Renaissance Mercantile Corp. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,675
+55,000 vol $0.085 each |
5,224,000 | |
| Filed 2023-08-01 08:41 Tx date 2023-07-31 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,000
+100,000 vol $0.08 each |
1,003,049 | |
| Filed 2023-07-26 16:06 Tx date 2023-07-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$8,000
+100,000 vol $0.08 each |
903,049 | |
| Filed 2023-02-27 15:26 Tx date 2023-02-24 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Renaissance Mercantile Corp. (Indirect Ownership)
|
Convertible Debentures Convertible Debenture .12 8% due February 24, 2026
16 - Acquisition or disposition under a prospectus exemption
|
$
+$500,000 vol $0.12 each |
$500,000 | |
| Filed 2023-02-27 14:04 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Renaissance Mercantile Corp. (Indirect Ownership)
|
Convertible Debentures Convertible Debenture .12 8% due February 24, 2026
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-12-20 15:06 Tx date 2022-12-19 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Pedram, Babak
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
| Filed 2022-12-20 15:03 Tx date 2022-11-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Pedram, Babak
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-11-28 09:56 Tx date 2022-11-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Pedram, Babak
4 - Director of Issuer
Holder: Pedram Holdings Limited (Control or Direction)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
| Filed 2022-11-28 09:50 Tx date 2022-11-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Pedram, Babak
4 - Director of Issuer
Holder: Pedram Holdings Limited (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
170,000 | ||
| Filed 2022-11-28 09:48 Tx date 2022-11-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Pedram, Babak
4 - Director of Issuer
Holder: Virtus Advisory Group Inc. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
28,500 | ||
| Filed 2022-11-28 09:47 Tx date 2022-11-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Pedram, Babak
4 - Director of Issuer
Holder: Virtus Advisory Group Inc. (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
400,000 | ||
| Filed 2022-10-05 11:04 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Nijjar, Harpreet
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$17,500
+175,000 vol $0.10 each |
175,000 | |
| Filed 2022-10-05 11:02 Tx date 2022-02-01 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Nijjar, Harpreet
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-10-04 16:00 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$20,000
+200,000 vol $0.10 each |
375,000 | |
| Filed 2022-09-27 11:46 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Williams, Mark
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,000,000 | |
| Filed 2022-09-27 11:42 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+175,000 vol |
175,000 | |
| Filed 2022-09-27 11:39 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-09-27 11:28 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+175,000 vol |
475,000 | |
| Filed 2022-09-26 16:45 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Smallbone, Sidney Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$20,000
+200,000 vol $0.10 each |
200,000 | |
| Filed 2022-09-26 16:39 Tx date 2022-02-15 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Smallbone, Sidney Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-08-10 09:15 Tx date 2022-07-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$25,000
+250,000 vol $0.10 each |
803,049 | |
| Filed 2022-07-29 16:16 Tx date 2022-07-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Fehr, Jeremy David
4 - Director of Issuer
Holder: 1761595 Alberta Ltd (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+100,000 vol $0.10 each |
700,000 | |
| Filed 2022-07-25 13:01 Tx date 2022-07-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Nijjar, Harpreet
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+100,000 vol $0.10 each |
100,000 | |
| Filed 2022-07-25 12:48 Tx date 2022-02-01 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Nijjar, Harpreet
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-07-25 12:47 Tx date 2022-07-19 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Nijjar, Harpreet
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+100,000 vol $0.10 each |
100,000 | |
| Filed 2022-07-25 12:46 Tx date 2022-02-01 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Nijjar, Harpreet
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-07-20 16:20 Tx date 2022-07-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abinvest Corporation (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$25,000
+250,000 vol $0.10 each |
280,000 | |
| Filed 2022-07-20 12:37 Tx date 2022-07-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Renaissance Mercantile Corp. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$15,000
+150,000 vol $0.10 each |
5,169,000 | |
| Filed 2022-05-19 15:53 Tx date 2022-05-19 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,150
+10,000 vol $0.115 each |
553,049 | |
| Filed 2022-05-12 16:00 Tx date 2022-05-12 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$625.00
+5,000 vol $0.125 each |
543,049 | |
| Filed 2022-04-12 16:18 Tx date 2022-04-12 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,950
+13,000 vol $0.15 each |
538,049 | |
| Filed 2022-04-07 16:21 Tx date 2022-04-07 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,965
+20,000 vol $0.1483 each |
525,049 | |
| Filed 2022-03-25 09:46 Tx date 2022-03-18 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abinvest Corporation (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,320
+30,000 vol $0.144 each |
30,000 | |
| Filed 2022-03-25 09:43 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Holder: Abinvest Corporation (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-03-02 15:49 Tx date 2022-03-02 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$950.00
+5,000 vol $0.19 each |
505,049 | |
| Filed 2022-01-18 11:48 Tx date 2022-01-17 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Renaissance Mercantile Corp. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,100
+5,000 vol $0.22 each |
5,009,000 | |
| Filed 2022-01-05 13:36 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Williams, Mark
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
500,000 | ||
| Filed 2021-10-14 13:27 Tx date 2021-10-13 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,000
-5,000 vol $0.20 each |
645,000 | |
| Filed 2021-09-23 11:28 Tx date 2021-09-22 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Matheson, Joseph Roderick
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Renaissance Mercantile Corp. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$760.00
+4,000 vol $0.19 each |
5,004,000 | |
| Filed 2021-07-20 12:30 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Fehr, Jeremy David
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
175,000 | ||
| Filed 2021-07-16 11:09 Tx date 2021-07-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+175,000 vol |
175,000 | |
| Filed 2021-07-16 11:05 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-16 11:02 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Johnson, Neil Allan
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
125,000 | ||
| Filed 2021-07-16 01:01 Tx date 2021-07-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Yan, Joanne
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$70,000
+175,000 vol $0.40 each |
510,000 | |
| Filed 2021-07-15 15:27 Tx date 2021-06-24 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
300,000 | ||
| Filed 2021-07-15 13:47 Tx date 2021-06-24 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
300,000 | ||
| Filed 2021-07-15 13:47 Tx date 2021-06-24 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-15 13:37 Tx date 2021-06-24 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
650,000 | ||
| Filed 2021-07-15 13:37 Tx date 2021-06-24 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
275,000 | ||
| Filed 2021-07-15 13:31 Tx date 2021-06-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-15 13:31 Tx date 2021-06-23 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-15 13:23 Tx date 2021-06-25 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-15 13:23 Tx date 2021-06-25 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-15 13:09 Tx date 2021-07-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Maddin, Preston
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$320,000
+800,000 vol $0.40 each |
800,000 | |
| Filed 2021-07-15 13:04 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Maddin, Preston
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-24 15:29 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-24 15:26 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-24 13:04 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Groot, Jacqueline
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|